Vivos Therapeutics VVOS 深 沪
已收盘 08-01 16:00:00 美东时间
5.18
+0.850
+19.63%
华盛通- 最 高5.6899
- 今 开4.15
- 成交量 98.29万股
- 最 低 4.10
- 昨 收 4.33
- 总市值 3050.76万
- 52周最高 7.95
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 1.98
- 委 比 -24.12%
- 总股本 588.95万
- 历史最高 360.25
- 量 比 8.52
- 振 幅 36.72%
- 历史最低 1.91
- 每 手 1
- 风险率 4.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vivos Therapeutics Adds to Management Team to Support Expansion and Growth
<p>Vivos Therapeutics, Inc. (NASDAQ: VVOS) 宣布两项关键任命——Michael Bruhn 担任执行副总裁，负责业务整合运营，以及 Dr. Terry Jones 任高级副总裁，负责人力资源，以支持其在睡眠测试中心和患者治疗服务方面的扩展。Bruhn 将推动公司在东海岸的业务扩展及新收购的整合，而 Jones 则将加强公司的人力资源管理。两人的加入体现了 Vivos 在新业务模式下快速增长的承诺。Vivos 目前正在积极寻求类似收购以提升收入。</p>
07-30 12:45
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neurogene (NASDAQ:NGNE) shares increased by 32.3% to $19.77 during Tue...
07-02 01:05
Vivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance
Vivos Therapeutics' FDA-cleared VidaSleep™ oral appliance has been approved by CMS for treating mild to moderate obstructive sleep apnea (OSA) and snoring, benefiting millions of Medicare beneficiaries. With over 80% of U.S. OSA cases undiagnosed, Vivos' dual-PDAC approval positions it as the only company with two Medicare-covered oral appliances, addressing a significant portion of the $36 billion sleep therapy market. The VidaSleep™ device, fea...
07-01 12:30
Vivos Therapeutics Announces European Journal Of Pediatrics Publishes Results Of Multicenter Clinical Trial Results For Treatment Of OSA In Children Using Vivos' Patented Daytime-Nighttime Appliance
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published
06-26 20:32
New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children
A recent study published in the European Journal of Pediatrics highlights that Vivos' Daytime-Nighttime Appliance (DNA) is a safe and effective non-surgical treatment for obstructive sleep apnea (OSA) in children, with 79% showing improvement and 17% achieving resolution. The device received FDA clearance in 2024 and offers a long-term alternative to adenotonsillectomy surgery, which often leads to relapse. Vivos' innovative solution aims to addr...
06-26 12:30
Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
Vivos Therapeutics, Inc. (NASDAQ: VVOS) has completed the acquisition of The Sleep Center of Nevada (SCN), the largest medical sleep center in Nevada, to expand its business model and capture higher-margin revenue. The transaction adds diagnostic and consulting revenues, as well as appliance treatment sales from SCN's patient base, marking Vivos’ first major acquisition of a sleep testing center. Vivos secured over $11 million in financing, inclu...
06-11 12:30
Vivos Therapeutics Secures $1.1M Convertible Note
Vivos Therapeutics ( ($VVOS) ) has provided an announcement. On May 21, 2025, V...
05-23 20:29
Vivos Therapeutics shares are trading lower after the company reported Q1 financial results and missed its EPS and revenue estimates.
Vivos Therapeutics shares are trading lower after the company reported Q1 finan...
05-16 22:54
Vivos Therapeutics Q1 EPS $(0.45) Misses $(0.40) Estimate, Sales $3.02M Miss $3.67M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.40) by 12.5 percent. This is a 72.39 percent increase over losses of $(1.63) per share
05-16 04:15
Earnings Scheduled For May 15, 2025
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is expected t...
05-15 16:32
